ENO1 and prostate carcinoma: Chen et al. showed that the ENO1 inhibitor HuL227 downregulates tumor growth, angiogenesis, and recruitment of CCR2+ inflammatory monocytes in the PC-3 subcutaneous xenograft model of prostate cancer [124].